Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2016 call → NOWe need to determine if management conveys that successive engagements of the same kind are coming in at progressively larger size. The question asks about a specific phenomenon: the unit size of the company's own repeatable business is escalating. We need to look for management's own words that compare against the company's own recent past, that it's already real and recurring, and that it's early. Scanning the transcript, there is discussion about new business growth, retention, renewal premium change, etc. But is there any mention of deals, orders, contracts, projects, customers, sites, or programs being individually larger, broader, or longer than before? The transcript talks about premium volume, new business growth, but not about the size of individual accounts or policies increasing. For example, in Business Insurance, they mention new business up 10%, but that's volume. They talk about retention and renewal premium change, but that's about pricing and exposure, not about the size of individual engagements. There is mention of Quantum Auto 2.0 and its success, but that's about a product, not about the size of individual policies. They talk about new business in Personal Insurance up 21%, but again that's volume. The question specifically asks about "successive engagements of the same kind" coming in at "progressively larger size." That would be like each new contract is bigger than the last. I don't see any such statement. Management talks about strong production, but not about the average size of policies or accounts increasing. They talk about retention and renewal premium change, which includes rate and exposure, but that's not about the unit size of new business. There is no mention of "larger deals" or "bigger projects" or anything like that. The closest might be that they are writing more business, but that's volume. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.